Vigil Neuroscience (VIGL) News Today $3.03 +0.14 (+4.84%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$3.05 +0.02 (+0.66%) As of 02/21/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL)February 20 at 11:17 AM | prnewswire.comVigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest UpdateVigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) was the target of a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 1,810,000 shares, an increase of 145.8% from the January 15th total of 736,500 shares. Currently, 9.4% of the company's shares are sold short. Based on an average daily volume of 1,010,000 shares, the short-interest ratio is presently 1.8 days.February 12, 2025 | marketbeat.comabrdn plc Buys 293,461 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL)abrdn plc increased its stake in Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) by 124.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 528,472 shares of the company's stock after buying an additional 293,461 sharFebruary 11, 2025 | marketbeat.comVigil Neuroscience Inc (VIGL) Receives a Buy from Stifel NicolausFebruary 10, 2025 | markets.businessinsider.comVigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech ConferenceJanuary 30, 2025 | globenewswire.comVigil Neuroscience reports data from Phase 1 trial on VG-3927January 24, 2025 | markets.businessinsider.comVigil Neuroscience (NASDAQ:VIGL) Receives "Buy" Rating from GuggenheimGuggenheim reiterated a "buy" rating on shares of Vigil Neuroscience in a research report on Friday.January 24, 2025 | marketbeat.comVigil Neuroscience: Now A 'Hold' Based On Two New Pipeline DevelopmentsJanuary 24, 2025 | seekingalpha.comVigil Neuroscience shares rise on positive Alzheimer's trial dataJanuary 23, 2025 | msn.comVigil Neuroscience’s VG-3927: Promising Phase 1 Results and Strategic Positioning for Phase 2January 23, 2025 | markets.businessinsider.comOptimistic Outlook for Vigil Neuroscience Inc: Promising Phase 1 Results and Strategic Partnership Potential for VG-3927January 23, 2025 | markets.businessinsider.comVigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s DiseaseJanuary 23, 2025 | finance.yahoo.comVigil Neuroscience gains as Alzheimer’s drug reaches mid-stage trialJanuary 23, 2025 | msn.comHC Wainwright Reiterates "Buy" Rating for Vigil Neuroscience (NASDAQ:VIGL)HC Wainwright restated a "buy" rating and set a $17.00 price objective on shares of Vigil Neuroscience in a research report on Thursday.January 23, 2025 | marketbeat.comVigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer's DiseaseJanuary 23, 2025 | globenewswire.comQ4 Earnings Forecast for VIGL Issued By William BlairVigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - Research analysts at William Blair issued their Q4 2024 earnings estimates for Vigil Neuroscience in a research report issued on Wednesday, January 8th. William Blair analyst S. Schram forecasts that the company will post earnings of ($0.20)January 13, 2025 | marketbeat.comVigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 MilestonesJanuary 8, 2025 | globenewswire.comVigil Neuroscience, Inc. (NASDAQ:VIGL) Director Haeberlein Samantha L. Budd Purchases 12,000 SharesVigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) Director Haeberlein Samantha L. Budd purchased 12,000 shares of the firm's stock in a transaction dated Thursday, December 19th. The shares were bought at an average price of $1.71 per share, with a total value of $20,520.00. Following the purchase, the director now owns 12,000 shares in the company, valued at $20,520. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.December 19, 2024 | marketbeat.comBuy Rating for Vigil Neuroscience Inc: Confidence in Microglial Biology Strategy Amid Market ChallengesDecember 10, 2024 | markets.businessinsider.comInsider Buying: Vigil Neuroscience, Inc. (NASDAQ:VIGL) CEO Buys 5,000 Shares of StockDecember 6, 2024 | insidertrades.comEquities Analysts Issue Forecasts for VIGL FY2024 EarningsVigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - Equities researchers at William Blair issued their FY2024 earnings estimates for shares of Vigil Neuroscience in a report issued on Tuesday, December 3rd. William Blair analyst S. Schram forecasts that the company will earn ($2.00) per shareDecember 6, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN), Trevi Therapeutics (TRVI) and Vigil Neuroscience Inc (VIGL)December 5, 2024 | markets.businessinsider.comWilliam Blair Initiates Coverage of Vigil Neuroscience (VIGL) with Outperform RecommendationDecember 5, 2024 | msn.comVigil Neuroscience: Down On A Competitor's FailureDecember 3, 2024 | seekingalpha.comOptimistic Buy Rating for Vigil Neuroscience Amid Market OverreactionNovember 28, 2024 | markets.businessinsider.comPromising Potential of Vigil Neuroscience’s VG-3927 in Alzheimer’s Treatment with a Buy Rating and $17 Price TargetNovember 26, 2024 | markets.businessinsider.comVigil Neuroscience (NASDAQ:VIGL) Given "Market Outperform" Rating at JMP SecuritiesJMP Securities restated a "market outperform" rating and set a $22.00 target price on shares of Vigil Neuroscience in a research report on Tuesday.November 26, 2024 | marketbeat.comBullish Outlook on Vigil Neuroscience Inc. Amid Promising Clinical Data and Unique TREM2 Biology FocusNovember 21, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Joint (JYNT), Vigil Neuroscience Inc (VIGL) and Definitive Healthcare Corp (DH)November 9, 2024 | markets.businessinsider.comVigil Neuroscience Advances Key Clinical ProgramsNovember 9, 2024 | markets.businessinsider.comVigil Neuroscience (NASDAQ:VIGL) Price Target Raised to $24.00Wedbush boosted their price objective on Vigil Neuroscience from $23.00 to $24.00 and gave the stock an "outperform" rating in a research note on Friday.November 8, 2024 | marketbeat.comVigil Neuroscience's (VIGL) Buy Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $17.00 target price on shares of Vigil Neuroscience in a report on Friday.November 8, 2024 | marketbeat.comVigil Neuroscience, Inc. (NASDAQ:VIGL) has caught the attention of institutional investors who hold a sizeable 41% stakeNovember 8, 2024 | finance.yahoo.comVigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 8, 2024 | markets.businessinsider.comVigil Neuroscience to Present at Guggenheim Healthcare Innovation ConferenceNovember 5, 2024 | markets.businessinsider.comabrdn plc Makes New $799,000 Investment in Vigil Neuroscience, Inc. (NASDAQ:VIGL)abrdn plc purchased a new stake in Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 235,011 shares of the company's stock, valued at approximately $799,000. abrdn plcNovember 5, 2024 | marketbeat.comStifel Nicolaus Sticks to Its Buy Rating for Vigil Neuroscience Inc (VIGL)October 19, 2024 | markets.businessinsider.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL)October 9, 2024 | prnewswire.comBuy Rating Affirmed for Vigil Neuroscience Inc Amid Promising Alzheimer’s Treatment PotentialOctober 9, 2024 | markets.businessinsider.comPoint72 Asset Management L.P. Buys New Position in Vigil Neuroscience, Inc. (NASDAQ:VIGL)Point72 Asset Management L.P. purchased a new position in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 1,485,000 shares of the company's stock, valuedOctober 2, 2024 | marketbeat.comEnsign Peak Advisors Inc Buys 166,442 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL)Ensign Peak Advisors Inc grew its stake in Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) by 72.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 395,116 shares of the company's stock after acquiringSeptember 29, 2024 | marketbeat.comVigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Down 20.3% in SeptemberVigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) was the recipient of a significant decrease in short interest in the month of September. As of September 15th, there was short interest totalling 546,600 shares, a decrease of 20.3% from the August 31st total of 685,800 shares. Based on an average daily volume of 488,600 shares, the days-to-cover ratio is currently 1.1 days. Approximately 2.7% of the company's shares are sold short.September 27, 2024 | marketbeat.comFDA lifts partial clinical hold on Vigil Neuroscience’s Phase I VG-3927 trialSeptember 20, 2024 | msn.comBuy Rating Affirmed for Vigil Neuroscience Inc. as FDA Lifts Clinical Hold and Phase 1 Trials Show PromiseSeptember 18, 2024 | markets.businessinsider.comVigil Neuroscience Says FDA Lifts Partial Hold Alzheimer's-Treatment TrialSeptember 17, 2024 | marketwatch.comVigil says FDA removed partial hold on Alzheimer’s candidateSeptember 17, 2024 | msn.comVigil Neuroscience, Inc.: Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927September 17, 2024 | finanznachrichten.deVigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927September 17, 2024 | globenewswire.comVigil Neuroscience to Present at Cantor Global Healthcare ConferenceSeptember 16, 2024 | globenewswire.comVigil Neuroscience (NASDAQ:VIGL) Trading Up 5%Vigil Neuroscience (NASDAQ:VIGL) Trading 5% HigherSeptember 10, 2024 | marketbeat.com Get Vigil Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for VIGL and its competitors with MarketBeat's FREE daily newsletter. Email Address VIGL Media Mentions By Week VIGL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VIGL News Sentiment▼0.000.60▲Average Medical News Sentiment VIGL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VIGL Articles This Week▼12▲VIGL Articles Average Week Get Vigil Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for VIGL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CDXC News Today KMDA News Today MREO News Today ERAS News Today TKNO News Today SIGA News Today SAGE News Today ZVRA News Today ETON News Today ALLO News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VIGL) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vigil Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vigil Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
